Abstract:OBJECTIVE:To explore the effects of cannabinoid 2 receptor (CB2) in the development of bone cancer pain in mice.METHODS:A total of 84 mice (C3H/HeJ) were randomly divided into 4 groups:tumor group (Group T, n = 30), medication administration group (Group J, n = 12), vehicle group (Group D, n = 12) and sham group (Group S, n = 30). And 2 × 10(5) osteolytic NCTC2472 cells in α-MEM were injected into medullary cavity of right distal femur to induce bone cancer pain in a murine model while sham mice received an injection of only α-MEM. All mice were tested for pain-related behaviors at pre-inoculation and at Days 5, 7, 10 and 14 post-inoculation. The tests included paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). Group J and Group D were injected intrathecally with 2 µg JWH015 dissolved in 4% DMSO and only 4% DMSO respectively in a 5 µl. volume. Pain behavior tests were performed before and at 1, 6, 24, 48 and 72 h after an intrathecal injection. Lumbar intumescentia of mice in each group were harvested to examine the expression level of CB2 by Western blot after pain behavior tests at Days 5, 7, 10 and 14 post-inoculation and 12 h after an intrathecal injection.RESULTS:(1) Pain behavior tests:Mechanical allodynia appeared at Day 7 post-inoculation. The value of PWMT was (1.27 ± 0.28) g (P < 0.05) and it declined gradually to (0.53 ± 0.20) g at Day 14. The threshold of mechanical hyperalgesia increased to (1.00 ± 0.20) g at 6 h after an intrathecal injection of JWH015, peaked at (1.40 ± 0.39) g at 12 h, became alleviated after 48 h and recovered to the pre-dosing levels at 72 h. Thermal hyperalgesia appeared at Day 10 post-inoculation. The value of PWTL was (16.9 ± 0.4) s (P < 0.05) at Day 10 and declined to (11.5 ± 0.7) s at Day 14 post-inoculation. The threshold of thermal hyperalgesia increased to (15.7 ± 1.9) g at 6 h after an intrathecal injection of JWH015, peaked at (18.6 ± 2.3) g at 12 h, became alleviated after 48 h and recovered to the pre-dosing levels at 72 h. (2) Western blot: From Day 5 post-inoculation, the ratio of CB2/β-actin increased gradually. Compared with the ratio of 0.190 ± 0.010 at Day 5 post-inoculation, the ratio of CB2/β-actin increased to 0.660 ± 0.010 at Day 14 post-inoculation (P < 0.05); compared with the ratio of 0.903 ± 0.006 in group D at 12 h after an intrathecal injection of JWH015, the ratio of CB2/β-actin 0.510 ± 0.010 significantly decreased (P < 0.05).CONCLUSION:The cannabinoid 2 receptor plays an important role in the formation of bone cancer pain.

The Inhibitor of Calcium/calmodulin-Dependent Protein Kinase II KN93 Attenuates Bone Cancer Pain Via Inhibition of KIF17/NR2B Trafficking in Mice

Participation of spinal CaMKII-NR2B signal pathway in the development of bone cancer pain in mice

Kinesin Superfamily Protein 17 Contributes to the Development of Bone Cancer Pain by Participating in Nr2b Transport in the Spinal Cord of Mice

Involvement of the Spinal NMDA Receptor/pkcγ Signaling Pathway in the Development of Bone Cancer Pain

Intrathecal Injection of Selected Peptide Myr-RC-13 Attenuates Bone Cancer Pain by Inhibiting KIF17 and NR2B Expression

Effects of Repeated Intrathecally KIF17 Antisense Oligodeoxynucleotide on the Expression of Mlin10 and NR2B in Spinal Cord in a Mouse Model of Bone Cancer Pain

Effect of intrathecal different dose of kinesin superfamily 17 on the development of bone cancer pain in mice

Intrathecal Injection of the Peptide Myr-NR2B9c Attenuates Bone Cancer Pain Via Perturbing N-Methyl-D-Aspartate Receptor-PSD-95 Protein Interactions in Mice

The Role of N‐methyl‐d‐aspartate Receptor Subunit NR2B in Spinal Cord in Cancer Pain

Suppression of KCNQ/M (kv7) Potassium Channels in the Spinal Cord Contributes to the Sensitization of Dorsal Horn WDR Neurons and Pain Hypersensitivity in a Rat Model of Bone Cancer Pain.

Suppression of KCNQ/M (kv7) Potassium Channels in Dorsal Root Ganglion Neurons Contributes to the Development of Bone Cancer Pain in a Rat Model

Analgesic Efficacy of Intrathecal Injection of Competitive Kinesin Superfamily Protein 17 Antagonist in a Mouse Model of Bone Cancer Pain

Role of nitric oxide synthase in the development of bone cancer pain and effect of L‑NMMA.

Analgesic Effects of Adenylyl Cyclase Inhibitor NB001 on Bone Cancer Pain in a Mouse Model

Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord

Role of Cannabinoid 2 Receptor in the Development of Bone Cancer Pain

Activation of Spinal Mrgc-Gi-Nr2b-Nnos Signaling Pathway by Mas Oncogene-Related Gene C Receptor Agonist Bovine Adrenal Medulla 8-22 Attenuates Bone Cancer Pain in Mice

Targeting A-type K(+) Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model.

Cav3.2 T-Type calcium channels downregulation attenuates bone cancer pain induced by inhibiting IGF-1/ HIF-1α signaling pathway in the rat spinal cord

Regulatory role of PI3K/Akt/WNK1 signal pathway in mouse model of bone cancer pain

Positive Feedback Regulation Between Microrna‐132 and CREB in Spinal Cord Contributes to Bone Cancer Pain in Mice